卡培他滨对晚期胃癌患者复发转移指标表达的影响研究

Study on the effect of capecitabine on the expression of recurrence and metastasis indicators in patients with advanced gastric cancer

目的探讨卡培他滨对晚期胃癌患者复发转移指标的表达变化及生存质量的影响。方法选择本院2015年5月—2016年7月收治的86例晚期胃癌患者,依据患者的临床治疗方案,将患者分为对照组与观察组,每组43例。对照组患者给予常规对症支持治疗,观察组采用卡培他滨维持治疗,14 d为一个疗程,连续治疗6个周期。观察两组患者对血清指标改变状况及生存质量的影响。结果 (1)治疗前两组患者血清指标CEA、CA50、CA199和CA125指标比较差异无统计学意义(P>0.05),治疗后对照组与观察组各项指标与治疗前比较均降低,而观察组患者四项指标降低程度与对照组比较更为明显(P<0.05);(2)治疗后对照组的中位生存期为(7.51±0.50)月、1年生存率为53.49%(23/43)、2年生存率32.56%(14/43),观察组患者中位生存期为(12.12±0.47)月,1年生存率为81.40%(35/43),2年生存率为55.81%(24/43),两组患者中位生存期、1年生存率、2年生存率比较均有统计学差异性(P均<0.05)。结论卡培他滨用于晚期胃癌患者中,有效改善了患者预后的生存治疗,改善复发转移相关的血清指标水平,效果显著,安全性好,是临床上可以采用的维持治疗方法。

Objective To investigate the effect of capecitabine on expression changes of recurrence and metastasis indicators and quality of life of patients with advanced gastric cancer.Methods 86 patients with advanced gastric cancer admitted to our hospital from May 2015 to July 2016 were chosen.According to the patient's clinical treatment plan,the patients were divided into the control group and the maintenance group,and 43 cases in each group.Patients in the control group received routine symptomatic supportive care,maintenance group received capecitabine maintenance therapy,14 days is as a course of treatment,and continuous treatment for 6 cycles.The effects of changes in serum indicators and quality of life were observed in the two groups.Results There were no significant differences in serum index of CEA,CA50,CA199 and CA125 between the two groups before treatment (P>0.05).After treatment,the indexes of the control group and the observation group were lower than those before treatment,while the reduction of the four indicators in the observation group was more significant than that of the control group (P<0.05).The median survival of the control group after treatment was (7.51±0. 50)months,and the 1-year survival rate was 53.49%(23/43),the annual survival rate of 2years was 32.56% (14/43).The median survival time of the observation group was (12.12±0.47)months,the 1-year survival rate was 81.40%(35/43),and the 2-year survival rate was 55.81%(24/43).There were statistical significance in the median survival,1-year survival rate,and 2-year survival rate of the two groups (P<0.05).Conclusions Capecitabine is effective in improving the prognosis of patients with advanced gastric cancer,improving the prognosis of patients with prognosis and improving serum levels of recurrence and metastasis.The effect is significant and safe.It is a clinically available maintenance therapy.